Investigation of safety and efficacy of once-daily semaglutide in obese subjects without diabetes mellitus

Update Il y a 4 ans
Reference: U1111-1155-4660

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

To assess and compare the dose-response of five doses of once-daily semaglutide versus placebo in inducing and maintaining weight loss after 52 weeks in obese subjects without diabetes mellitus


Inclusion criteria

  • obesity